Franck Raeppel

USPTO Granted Patents = 13 (Patent Applications = 6)

CIPO Patents = 6 (Patent Applications = 3)

EPO Patents = 6 (Patent Applications = 5)

Average Co-Inventor Count = 7.4

ph-index = 2

Forward Citations = 20(Granted Patents)

Company Filing History:

Mirati Therapeutics, Inc.

patents

5. 1 out of 832,680

Other

patents

Years Active: 2010-2025

Loading Chart...

13 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12466838 - Crystalline form of a multi-tyrosine kinase inhibitor, method of preparation, and use thereof (2025-11-11),

2. 10738056 - Pyrazolopyrimidinone compounds and uses thereof (2020-08-11),

3. 9636298 - Prodrugs of compounds that enhance antifungal activity and compositions of said prodrugs (2017-05-02),

4. 9487474 - Imino compounds as protecting agents against ultraviolet radiations (2016-11-08),

5. 9018378 - Processes and intermediates for preparing fused heterocyclic kinase inhibitors (2015-04-28),

6. 8907091 - Processes and intermediates for preparing fused heterocyclic kinase inhibitors (2014-12-09),

7. 8906852 - Inhibitors of protein tyrosine kinase activity (2014-12-09),

8. 8470850 - Inhibitors of VEGF receptor and HGF receptor signalling (2013-06-25),

9. 8455484 - Selected inhibitors of protein tyrosine kinase activity (2013-06-04),

10. 8329726 - Inhibitors of VEGF receptor and HGF receptor signaling (2012-12-11),

11. 8093264 - Fused heterocycles as inhibitors of VEGF receptor and HGF receptor signaling (2012-01-10),

12. 7790729 - Inhibitors of VEGF receptor and HGF receptor signaling (2010-09-07),

13. 7772247 - Substituted thieno[3,2-d]pyridines as inhibitors of the VEGF receptor and HGF receptor (2010-08-10),

Title: The Innovative Inventor Franck Raeppel: A Pioneer in Pharmaceutical Discoveries

Introduction:

Franck Raeppel, a prolific inventor based in Montreal, CA, has made significant contributions to the field of pharmaceuticals with a total of 12 patents to his name. His groundbreaking inventions have focused on combating autoimmune, inflammatory, and neurodegenerative diseases, showcasing his dedication to advancing healthcare through innovative solutions.

Latest Patents:

Franck Raeppel's recent patents include the development of Pyrazolopyrimidinone compounds for treating various diseases. These compounds not only serve as potential treatments for autoimmune conditions but also demonstrate promise in addressing inflammatory and neurodegenerative disorders. Additionally, his work on prodrugs that enhance antifungal activity highlights his versatility in creating solutions for diverse medical challenges.

Career Highlights:

With an impressive portfolio of patents, Franck Raeppel has garnered recognition for his inventive spirit and scientific expertise. Having worked at notable companies like Methylgene, Inc., he has consistently pushed the boundaries of pharmaceutical research, bringing forth novel compounds and treatment methodologies that have the potential to revolutionize healthcare practices.

Collaborations:

Throughout his career, Franck Raeppel has collaborated with esteemed professionals in the field, including Arkadii Vaisburg and Stephen Claridge. These collaborations have not only enriched his innovative ventures but have also led to the development of impactful pharmaceutical solutions that benefit patients worldwide.

Conclusion:

In conclusion, Franck Raeppel stands as a leading figure in the realm of pharmaceutical inventions, with a remarkable track record of patents that signify his commitment to advancing healthcare through pioneering research and development. His contributions have undoubtedly left a lasting impact on the industry, shaping the future of medicine with his inventive creations.

This text is generated by artificial intelligence and may not be accurate.